![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.155 | 3.43% | 4.675 | 4.35 | 5.00 | - | 25,623 | 16:35:16 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.52 | 9.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
17/4/2020 13:29 | 40m in total split 12m end of March and 28m on Wednesday!Half of 28m is 14m and keep the rest for result | ![]() dave444 | |
17/4/2020 12:49 | They were issued at the end of march | ![]() dave444 | |
17/4/2020 12:43 | RBC on Gilead Sciences, Inc. - Reported Remdesivir Data Looks Encouraging on Surface, But Many Unknowns Impact: Incremental Positive Anecdotal data reported this afternoon from one of the sites in GILD's ongoing ph.III remdesivir program looks promising on the surface and continues to support some potential for the drug to be active in certain COVID-19 pts (unlike for HCQ, where emerging data continue to worsen). Nonetheless, there are major limitations to contextualizing and interpreting this data, and we see the GILD-sponsored moderate study reading out next month as offering the best opportunity for a true efficacy read. We continue to see remdesivir as more impactful to GILD's image and enabling recognition of their strong commercial portfolio and pipeline optionality, more so than a materially monetizable nearterm driver. | ![]() markinvestor | |
17/4/2020 12:24 | That's what's in the DM link above. | ![]() gbh2 | |
17/4/2020 12:19 | Remdesivir bulletin late last night was the only reason this dropped today, always was going to with competition seemingly ahead. Now it's been rumoured as rubbish this should Bolt SNG back up. Plus it's 2.5 days till next trade opportunity, and news may come in that time. All in still ? | slinkyj | |
17/4/2020 12:12 | I read 20million plus 20million so where are the remaining 12million? | ![]() jonnynixon | |
17/4/2020 12:10 | Some people will try anything for a few quid!! | ![]() 2nell | |
17/4/2020 12:06 | This could be knocking the steam out of the SP: | ![]() gbh2 | |
17/4/2020 11:56 | I'd have recommended 'the cat of nine tails' and 'walking the plank'. But I'm probably too understanding. ;o) | ![]() jev1 | |
17/4/2020 11:49 | Nobby...as regardTickboo...can I suggest six of the best and probation | ![]() kop202 | |
17/4/2020 11:46 | Well the chart is looking very nice indeed. Providing we can close above 58 it bodes well for next week which should see the start of the bounce back up. NSCI worked out well (for once) Sold half - Banking original investment + 50% profit. The other half on freeride. Decide to take another 15k SNG on that drop to 58 Also a maiden purchase in Sareum (SAR) ;-) GLA, DYOR, NAI fanny | ![]() fanramptastic mate | |
17/4/2020 11:24 | Fair enough. Nobby et al have done the same but yeah I was rather spammy. Noted. | ![]() tickboo | |
17/4/2020 11:03 | Only a matter of time now before the world knows about this drug. Positive results , safe to use and fast tracked into USA. Three pounds possible | ![]() imjustdandy | |
17/4/2020 11:01 | Synairgen have made it onto Wiki: hxxps://en.wikipedia Interferon beta[edit] UK biotech firm Synairgen started conducting trials on IFN-β, a drug that was originally developed to treat COPD.[8] IFN-β will be included in the international Solidarity Trial in combination with the HIV drugs Lopinavir and Ritonavir.[27] hxxps://en.wikipedia Drug candidates under study[edit] See also: COVID-19 drug development § Phase III-IV trials, and COVID-19 drug repurposing research The individual or combined drugs being studied in the Solidarity and Discovery projects are in separate trials and hospital sites internationally:[4][ remdesivir lopinavir/ritonavir combined lopinavir/ritonavir combined with interferon-beta hydroxychloroquine (or chloroquine) With about 15% of people infected by COVID-19 having severe illness, and hospitals being overwhelmed during the pandemic, WHO recognized a rapid clinical need to test and repurpose these drugs as agents already approved for other diseases and recognized as safe.[4] | ![]() makendon | |
17/4/2020 10:58 | Apologies for a pump but I thanked nobby for one and this also looks great value. A low market cap PLCs with great potential then check out MWG. Current market cap £6m with £20m spent on its tech and cash snd current orders worth half its market cap. Regardless of covid their tech is amazing snd protected. Given the issues with clean water which is only going to become more of an issue these guys are going to be massive. Sadly for early investors it's taken a lot of money, sweat and tears but now they'll start to bear the fruits of their labour with a more commercially minded BoD. A snip given cash in the bank, backdated orders to fulfil, increased production capacity with SKIN bearing the costs it's a great time to buy and added with the AI which is a bolt-in to existing clients | ![]() tickboo | |
17/4/2020 10:49 | This is looking very attractive compared to other covid stocks. Trial results getting closer. Also the placing at avacta was 18p - price now 70p. Our placing was 35p and price now 58p. Will rocket soon enough | ![]() imjustdandy | |
17/4/2020 10:46 | Dave - I don’t think the new ‘investorsR | ![]() talk2dubya | |
17/4/2020 10:33 | 28m were available in this part of the fundraising!I would imagine half will be sold so 14mIt should be clear by cv Tuesday | ![]() dave444 | |
17/4/2020 10:30 | We had 2 weeks of pain with the first lot of new shares, expect the same for a while before we get a blockbuster announcement that will be here before you know it! SWEET moment coming | thwarnts | |
17/4/2020 10:25 | Suspect the 40million new shares are slowly being cleared. 20million have definitely hit the market the other 20million is not on law?Based on the the full 40m verses the market cap earlier in the week this should be 50.8p. So you are right the market is valuing these higher through more shares and a lesser drop in share price. Bit more to go yet. This will keep dropping until next week imho as the shares get offloaded | ![]() jonnynixon | |
17/4/2020 10:21 | PAID 58P TO BUY | ![]() scoble2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions